Company Description
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States.
It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.
licensing arrangements and other strategic transactions to advance and maximize the value of certain product candidates and program for the treatment of retinal diseases and with Altanispac Labs for PL9643 for the treatment of dry eye disease; and oral PL8177 for the treatment inflammatory bowel diseases.
Palatin Technologies, Inc. was incorporated in 1986 and is based in Princeton, New Jersey.
| Country | United States |
| Founded | 1986 |
| IPO Date | Oct 28, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Carl Spana |
Contact Details
Address: 301 Carnegie Center Drive, Suite 304 Princeton, New Jersey 08540 United States | |
| Phone | 609 495 2200 |
| Website | palatin.com |
Stock Details
| Ticker Symbol | PTN |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0000911216 |
| CUSIP Number | 696077601 |
| ISIN Number | US6960776010 |
| Employer ID | 95-4078884 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Carl Spana Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Stephen T. Wills CPA, MST | Chief Financial Officer, Chief Operating Officer, Executive Vice President, Treasurer and Secretary |
| Burns McClellan | Vice President of Investor Relations |
| Stephen A. Slusher Esq. | Chief Legal Officer |
| James E. Hattersley B.A., M.S. | Senior Vice President of Business Development |
| John Dodd Ph.D. | Senior Vice President of Preclinical Development |
| Robert Jordan | Senior Vice President of Program Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 28, 2026 | 10-K | Annual Report |
| Aug 14, 2026 | SCHEDULE 13G/A | Filing |
| Aug 3, 2026 | 8-K | Current Report |
| Jun 25, 2026 | DEF 14A | Other definitive proxy statements |
| May 28, 2026 | CERT | Certification by an exchange approving securities for listing |
| May 28, 2026 | 8-A12B | Registration of securities |
| May 28, 2026 | 25 | Filing |
| May 18, 2026 | 8-K | Current Report |
| May 15, 2026 | SCHEDULE 13G/A | Filing |
| May 15, 2026 | SCHEDULE 13G/A | Filing |